Metastatic CRC with EGFR expression and KRAS wild-type: In combination with FOLFIRI in combination with irinotecan in patient’s refractory to irinotecan-based chemotherapy; as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. Here, KRAS is linked to colorectal carcinoma.